• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect Ent launches Nova sinus implant trial

July 9, 2015 By Fink Densford

Intersect Ent launches Nova sinus implant trialIntersect ENT (NSDQ:XENT) said yesterday it enrolled the 1st patient in a trial of its Nova bioabsorbable steroid releasing sinus implant.

The implant is designed to prop open the sinuses and deliver anti-inflammatory medication after surgical interventions, the Menlo Park, Calif.-based company said.

“Clinical evidence to date has shown that Propel and Propel mini meaningfully improve the outcomes of patients undergoing ethmoid sinus surgery. Patients with chronic sinusitis may benefit similarly from a steroid-releasing implant as part of treatment of the frontal sinus. I am pleased to be involved with the clinical assessment of both Propel mini and Nova and believe that each of these products has the potential to offer a differentiated solution in the continuum of care for patients with chronic sinusitis,” principal investigator Dr. Tim Smith of Oregon Health and Science University said in prepared remarks.

The 80-patient randomized, prospective trial is the 2nd of a cohort of the company’s Progress study, Intersect Ent said. The 1st 80-patient trial examined the company’s Propel mini drug eluting implant in hopes of receiving expanded indication for the drug-device combo.

“We are excited to commence enrollment in our pivotal study of Nova and to have completed enrollment in the Propel mini cohort of the Progress trial. Intersect ENT is committed to furthering clinical evidence that expands options for people suffering from sinusitis, a chronic condition that severely impacts quality of life,” CEO Lisa Earnhardt said in a press release.

Last month, Intersect Ent closed a public offering of 4.1 million shares of common stock at $25 per share, bringing in an approximate $103 million for the ear, nose and throat-focused device company.

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS